Spotlight On ATTR-CM
Welcome to Spotlight On ATTR-CM, your go-to source for the latest research, diagnostic advancements, and therapeutic strategies in transthyretin amyloid cardiomyopathy (ATTR-CM). Join leading cardiologists and researchers as they share their insights on this intricate condition to enhance patient care and outcomes.
Episodes 1-11 of 11
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Heart MattersComplexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Advances in Care for ATTR-CM: Current and Emerging Strategies
Heart MattersAdvances in Care for ATTR-CM: Current and Emerging Strategies
Treating ATTR-CM: Current Strategies and Emerging Options
Heart MattersTreating ATTR-CM: Current Strategies and Emerging Options
Addressing Unmet Needs in ATTR-CM Care: Key Considerations for Optimal Management
Heart MattersAddressing Unmet Needs in ATTR-CM Care: Key Considerations for Optimal Management
Overcoming Challenges in ATTR-CM Care: Best Practices for Accurate Diagnosis
Heart MattersOvercoming Challenges in ATTR-CM Care: Best Practices for Accurate Diagnosis
Understanding the Pathophysiology Behind ATTR-CM
Heart MattersUnderstanding the Pathophysiology Behind ATTR-CM
Cost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
Heart MattersCost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
ATTR-CM Screening: How Economic Factors Can Impact Care
Heart MattersATTR-CM Screening: How Economic Factors Can Impact Care
Patient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Heart MattersPatient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Spotlight On ATTR-CMSilent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Spotlight On ATTR-CMVutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
